{"pmid":32490506,"title":"Coronavirus disease 2019 (COVID-19) and simultaneous acute anteroseptal and inferior ST-segment elevation myocardial infarction.","text":["Coronavirus disease 2019 (COVID-19) and simultaneous acute anteroseptal and inferior ST-segment elevation myocardial infarction.","Coronavirus disease 2019 (COVID-19) is a recently recognised pandemic spreading rapidly from Wuhan, Hubei, to other provinces in China and to many countries around the world. The number of COVID-19-related deaths is steadily increasing. Acute ST-segment elevation myocardial infarction (STEMI) is a disease with high morbidity and mortality rates, and primary percutaneous coronary intervention is usually recommended for the treatment. A patient with diabetes mellitus and hypertension for five years was admitted to the emergency unit with symptoms of fever, cough and dyspnoea. These symptoms were consistent with viral pneumonia and a COVID PCR test was performed, which tested positive three days later. The patient had chest pain on the eighth day of hospitalisation. On electrocardiography, simultaneous acute inferior and anterior STEMI were identified. High levels of stress and increased metabolic demand in these patients may lead to concomitant thrombosis of different coronary arteries, presenting with two different STEMIs.","Cardiovasc J Afr","Yolcu, Mustafa","Gunesdogdu, Fusun","Bektas, Metin","Bayirli, Derya Turan","Serefhanoglu, Kivanc","32490506"],"abstract":["Coronavirus disease 2019 (COVID-19) is a recently recognised pandemic spreading rapidly from Wuhan, Hubei, to other provinces in China and to many countries around the world. The number of COVID-19-related deaths is steadily increasing. Acute ST-segment elevation myocardial infarction (STEMI) is a disease with high morbidity and mortality rates, and primary percutaneous coronary intervention is usually recommended for the treatment. A patient with diabetes mellitus and hypertension for five years was admitted to the emergency unit with symptoms of fever, cough and dyspnoea. These symptoms were consistent with viral pneumonia and a COVID PCR test was performed, which tested positive three days later. The patient had chest pain on the eighth day of hospitalisation. On electrocardiography, simultaneous acute inferior and anterior STEMI were identified. High levels of stress and increased metabolic demand in these patients may lead to concomitant thrombosis of different coronary arteries, presenting with two different STEMIs."],"journal":"Cardiovasc J Afr","authors":["Yolcu, Mustafa","Gunesdogdu, Fusun","Bektas, Metin","Bayirli, Derya Turan","Serefhanoglu, Kivanc"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32490506","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10-5830-CVJA-2020-016","keywords":["covid-19","acute anterior wall myocardial infarction","acute inferior wall myocardial infarction"],"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1668623433636773889,"score":9.490897,"similar":[{"pmid":32471712,"title":"Treatment of ST-segment elevation myocardial infarction during COVID-19 pandemic.","text":["Treatment of ST-segment elevation myocardial infarction during COVID-19 pandemic.","The number of cases of the coronavirus-induced disease-2019 (COVID-19) continues to increase exponentially worldwide. In this crisis situation, the management of ST-segment elevation myocardial infarction (STEMI) is challenging. In this review, we outline the risk and benefits of primary PCI vs. thrombolysis for STEMI. While thrombolysis may seem like a good choice, many patients have a contraindication and could end-up using more resources. Also, with a high probability of the angiogram showing non-obstructed coronary arteries during acute infections, primary PCI should be the preferred strategy.","Cardiovasc Revasc Med","Yerasi, Charan","Case, Brian C","Forrestal, Brian J","Chezar-Azerrad, Chava","Hashim, Hayder","Ben-Dor, Itsik","Satler, Lowell F","Mintz, Gary S","Waksman, Ron","32471712"],"abstract":["The number of cases of the coronavirus-induced disease-2019 (COVID-19) continues to increase exponentially worldwide. In this crisis situation, the management of ST-segment elevation myocardial infarction (STEMI) is challenging. In this review, we outline the risk and benefits of primary PCI vs. thrombolysis for STEMI. While thrombolysis may seem like a good choice, many patients have a contraindication and could end-up using more resources. Also, with a high probability of the angiogram showing non-obstructed coronary arteries during acute infections, primary PCI should be the preferred strategy."],"journal":"Cardiovasc Revasc Med","authors":["Yerasi, Charan","Case, Brian C","Forrestal, Brian J","Chezar-Azerrad, Chava","Hashim, Hayder","Ben-Dor, Itsik","Satler, Lowell F","Mintz, Gary S","Waksman, Ron"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32471712","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.carrev.2020.05.027","keywords":["covid-19","fibrinolytics","primary percutaneous coronary intervention","stemi"],"topics":["Prevention"],"weight":1,"_version_":1668255193421053952,"score":376.59296},{"pmid":32352633,"title":"Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID-19 in ST-segment elevation myocardial infarction patients.","text":["Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID-19 in ST-segment elevation myocardial infarction patients.","Important health resources are dedicated worldwide to the management of COVID-19. This new disease, due to its large diffusion, may significantly hamper the prognosis of other pathologies, such as ST-segment elevation myocardial infarction (STEMI) because of (a) a possible direct negative impact and (b) shortage of first response medical resources and increased delays to reperfusion. We report the case of a 68-year-old man admitted for anterior STEMI and asymptomatic COVID-19. Due to extended transportation delays to a cathlab, he received intravenous fibrinolytic therapy, which failed. Reperfusion was achieved with rescue coronary angioplasty, but the patient experienced two episodes of acute stent thrombosis at 2- and 36-hr following admission and despite optimal medical therapy. He finally died because of cardiogenic shock. This raises concerns about a possible increase in platelet aggregability associated with COVID-19 leading to an increased risk of stent thrombosis, particularly in the context of STEMI. This pleads for the promotion of primary coronary angioplasty as the first-choice revascularization technique in this population and the use of new generation P2Y12 inhibitors. In addition, the use of GPIIb/IIIa inhibitors may be considered in every STEMI patient with COVID-19 to prevent the risk of acute stent thrombosis.","Catheter Cardiovasc Interv","Lacour, Thibaud","Semaan, Carl","Genet, Thibaud","Ivanes, Fabrice","32352633"],"abstract":["Important health resources are dedicated worldwide to the management of COVID-19. This new disease, due to its large diffusion, may significantly hamper the prognosis of other pathologies, such as ST-segment elevation myocardial infarction (STEMI) because of (a) a possible direct negative impact and (b) shortage of first response medical resources and increased delays to reperfusion. We report the case of a 68-year-old man admitted for anterior STEMI and asymptomatic COVID-19. Due to extended transportation delays to a cathlab, he received intravenous fibrinolytic therapy, which failed. Reperfusion was achieved with rescue coronary angioplasty, but the patient experienced two episodes of acute stent thrombosis at 2- and 36-hr following admission and despite optimal medical therapy. He finally died because of cardiogenic shock. This raises concerns about a possible increase in platelet aggregability associated with COVID-19 leading to an increased risk of stent thrombosis, particularly in the context of STEMI. This pleads for the promotion of primary coronary angioplasty as the first-choice revascularization technique in this population and the use of new generation P2Y12 inhibitors. In addition, the use of GPIIb/IIIa inhibitors may be considered in every STEMI patient with COVID-19 to prevent the risk of acute stent thrombosis."],"journal":"Catheter Cardiovasc Interv","authors":["Lacour, Thibaud","Semaan, Carl","Genet, Thibaud","Ivanes, Fabrice"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32352633","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/ccd.28948","keywords":["acute myocardial infarction","antithrombotic treatment","viral infection"],"topics":["Case Report"],"weight":1,"_version_":1666138495758893056,"score":375.75897},{"pmid":32337148,"pmcid":"PMC7179991","title":"Corona Virus Disease 2019 (COVID-19) Presenting as Acute ST Elevation Myocardial Infarction.","text":["Corona Virus Disease 2019 (COVID-19) Presenting as Acute ST Elevation Myocardial Infarction.","Patients with Covid-19 disease commonly present with symptoms related to respiratory illness, and less commonly they develop cardiovascular complications either on presentation or during the course of the disease. The mortality/morbidity is high in these patients with cardiovascular involvement. Acute ST-elevation myocardial infarction (STEMI) is a medical emergency which needs immediate coronary re-perfusion for better patient outcomes. Here we present a patient who presented to the emergency room with acute STEMI and later tested positive for COVID-19. She was successfully treated with coronary revascularization and stent placement, and remains on the ventilator to date as she quickly developed acute respiratory distress syndrome. We need more research in Covid-19 patients with cardiovascular involvement for early diagnosis, prevention of exposure to health care workers and effective treatment.","Cureus","Siddamreddy, Suman","Thotakura, Ramakrishna","Dandu, Vasuki","Kanuru, Sruthi","Meegada, Sreenath","32337148"],"abstract":["Patients with Covid-19 disease commonly present with symptoms related to respiratory illness, and less commonly they develop cardiovascular complications either on presentation or during the course of the disease. The mortality/morbidity is high in these patients with cardiovascular involvement. Acute ST-elevation myocardial infarction (STEMI) is a medical emergency which needs immediate coronary re-perfusion for better patient outcomes. Here we present a patient who presented to the emergency room with acute STEMI and later tested positive for COVID-19. She was successfully treated with coronary revascularization and stent placement, and remains on the ventilator to date as she quickly developed acute respiratory distress syndrome. We need more research in Covid-19 patients with cardiovascular involvement for early diagnosis, prevention of exposure to health care workers and effective treatment."],"journal":"Cureus","authors":["Siddamreddy, Suman","Thotakura, Ramakrishna","Dandu, Vasuki","Kanuru, Sruthi","Meegada, Sreenath"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32337148","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.7759/cureus.7782","keywords":["acute respiratory distress syndrome","atypical covid","covid-19","stemi"],"topics":["Case Report"],"weight":1,"_version_":1666138494275158017,"score":355.1965},{"pmid":32425198,"pmcid":"PMC7229476","title":"North American COVID-19 ST-segment elevation myocardial infarction (NACMI) registry: Rationale, design, and implications.","text":["North American COVID-19 ST-segment elevation myocardial infarction (NACMI) registry: Rationale, design, and implications.","Background: The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that causes coronavirus disease 2019 (COVID-19), has resulted in a global pandemic. Patients with cardiovascular risk factors or established cardiovascular disease are more likely to experience severe or critical COVID-19 illness and myocardial injury is a key extra-pulmonary manifestation. These patients frequently present with ST-elevation on an electrocardiogram (ECG) due to multiple etiologies including obstructive, non-obstructive, and/or angiographically normal coronary arteries. The incidence of ST-elevation myocardial infarction (STEMI) mimics in COVID-19 positive hospitalized patients, and the association with morbidity and mortality is unknown. Understanding the natural history and appropriate management of COVID-19 patients presenting with ST elevation is essential to inform patient management decisions and protect healthcare workers. Methods: The Society for Cardiovascular Angiography and Interventions (SCAI) and The Canadian Association of Interventional Cardiology (CAIC) in conjunction with the American College of Cardiology Interventional Council have collaborated to create a multi-center observational registry, North American COVID-19 ST-Segment Elevation Myocardial Infarction (NACMI). This registry will enroll confirmed COVID-19 patients and persons under investigation (PUI) with new ST-segment elevation or new onset left bundle branch block (LBBB) on the ECG with clinical suspicion of myocardial ischemia. We will compare demographics, clinical findings, outcomes and management of these patients with a historical control group of over 15,000 consecutive STEMI activation patients from the Midwest STEMI Consortium using propensity matching. The primary clinical outcome will be in- hospital major adverse cardiovascular events (MACE) defined as composite of all-cause mortality, stroke, recurrent MI, and repeat unplanned revascularization in COVID-19 confirmed or PUI. Secondary outcomes will include the following: reporting of etiologies of ST Elevation; cardiovascular mortality due to myocardial infarction, cardiac arrest and /or shock; individual components of the primary outcome; composite primary outcome at one year; as well as ECG and angiographic characteristics. Conclusion: The multicenter NACMI registry will collect data regarding ST elevation on ECG in COVID-19 patients to determine the etiology and associated clinical outcomes. The collaboration and speed with which this registry has been created, refined, and promoted serves as a template for future research endeavors.","Am Heart J","Dehghani, Payam","Davidson, Laura J","Grines, Cindy L","Nayak, Keshav","Saw, Jackie","Kaul, Prashant","Bagai, Akshay","Garberich, Ross","Schmidt, Christian","Ly Md Sm, Hung Q","Giri, Jay","Meraj, Perwaiz","Shah, Binita","Garcia, Santiago","Sharkey, Scott","Wood, David A","Welt, Frederick G","Mahmud, Ehtisham M","Henry, Timothy D","32425198"],"abstract":["Background: The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that causes coronavirus disease 2019 (COVID-19), has resulted in a global pandemic. Patients with cardiovascular risk factors or established cardiovascular disease are more likely to experience severe or critical COVID-19 illness and myocardial injury is a key extra-pulmonary manifestation. These patients frequently present with ST-elevation on an electrocardiogram (ECG) due to multiple etiologies including obstructive, non-obstructive, and/or angiographically normal coronary arteries. The incidence of ST-elevation myocardial infarction (STEMI) mimics in COVID-19 positive hospitalized patients, and the association with morbidity and mortality is unknown. Understanding the natural history and appropriate management of COVID-19 patients presenting with ST elevation is essential to inform patient management decisions and protect healthcare workers. Methods: The Society for Cardiovascular Angiography and Interventions (SCAI) and The Canadian Association of Interventional Cardiology (CAIC) in conjunction with the American College of Cardiology Interventional Council have collaborated to create a multi-center observational registry, North American COVID-19 ST-Segment Elevation Myocardial Infarction (NACMI). This registry will enroll confirmed COVID-19 patients and persons under investigation (PUI) with new ST-segment elevation or new onset left bundle branch block (LBBB) on the ECG with clinical suspicion of myocardial ischemia. We will compare demographics, clinical findings, outcomes and management of these patients with a historical control group of over 15,000 consecutive STEMI activation patients from the Midwest STEMI Consortium using propensity matching. The primary clinical outcome will be in- hospital major adverse cardiovascular events (MACE) defined as composite of all-cause mortality, stroke, recurrent MI, and repeat unplanned revascularization in COVID-19 confirmed or PUI. Secondary outcomes will include the following: reporting of etiologies of ST Elevation; cardiovascular mortality due to myocardial infarction, cardiac arrest and /or shock; individual components of the primary outcome; composite primary outcome at one year; as well as ECG and angiographic characteristics. Conclusion: The multicenter NACMI registry will collect data regarding ST elevation on ECG in COVID-19 patients to determine the etiology and associated clinical outcomes. The collaboration and speed with which this registry has been created, refined, and promoted serves as a template for future research endeavors."],"journal":"Am Heart J","authors":["Dehghani, Payam","Davidson, Laura J","Grines, Cindy L","Nayak, Keshav","Saw, Jackie","Kaul, Prashant","Bagai, Akshay","Garberich, Ross","Schmidt, Christian","Ly Md Sm, Hung Q","Giri, Jay","Meraj, Perwaiz","Shah, Binita","Garcia, Santiago","Sharkey, Scott","Wood, David A","Welt, Frederick G","Mahmud, Ehtisham M","Henry, Timothy D"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425198","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.ahj.2020.05.006","locations":["North American","North American"],"topics":["Treatment"],"weight":1,"_version_":1667252837717901312,"score":351.76035},{"pmid":32473051,"title":"Massive coronary thrombosis caused primary percutaneous coronary intervention to fail in a COVID-19 patient with ST-elevation myocardial infarction.","text":["Massive coronary thrombosis caused primary percutaneous coronary intervention to fail in a COVID-19 patient with ST-elevation myocardial infarction.","COVID-19 is a new viral infection that has a significant impact on global health and economy. Because of its rapid spread worldwide, it may influence the prognosis of other medical conditions, such as ST-segment elevation myocardial infarction (STEMI). We report a case of a 58-year female patient admitted with an infero-posterior STEMI on the background of recently positive COVID-19 swab. Reperfusion was attempted through primary PCI but unfortunately failed to restore coronary blood flow due to massive thrombotic burden despite several attempts of balloon dilatation and aspiration thrombectomy. She sadly died later on because of hemodynamic deterioration. This scenario raises concerns about Neutrophil Extracellular Traps (NETS) which might potentially have propagated inflammation and thrombosis via platelets' aggregation leading to enhanced coagulopathy and massive coronary thrombosis. Therefore, we suggest primary PCI as the first-choice of revascularization in patients with combined COVID-19 and STEMI. Additionally, we emphasize on the importance of using the potent new generation P2Y12 inhibitors along with GPIIb/IIIa inhibitors in every STEMI patient with COVID-19 to achieve favorable conditions for primary PCI as well as favorable outcomes after stent implantation.","Catheter Cardiovasc Interv","Seif, Sherif","Ayuna, Ahmed","Kumar, Abhishek","Macdonald, John","32473051"],"abstract":["COVID-19 is a new viral infection that has a significant impact on global health and economy. Because of its rapid spread worldwide, it may influence the prognosis of other medical conditions, such as ST-segment elevation myocardial infarction (STEMI). We report a case of a 58-year female patient admitted with an infero-posterior STEMI on the background of recently positive COVID-19 swab. Reperfusion was attempted through primary PCI but unfortunately failed to restore coronary blood flow due to massive thrombotic burden despite several attempts of balloon dilatation and aspiration thrombectomy. She sadly died later on because of hemodynamic deterioration. This scenario raises concerns about Neutrophil Extracellular Traps (NETS) which might potentially have propagated inflammation and thrombosis via platelets' aggregation leading to enhanced coagulopathy and massive coronary thrombosis. Therefore, we suggest primary PCI as the first-choice of revascularization in patients with combined COVID-19 and STEMI. Additionally, we emphasize on the importance of using the potent new generation P2Y12 inhibitors along with GPIIb/IIIa inhibitors in every STEMI patient with COVID-19 to achieve favorable conditions for primary PCI as well as favorable outcomes after stent implantation."],"journal":"Catheter Cardiovasc Interv","authors":["Seif, Sherif","Ayuna, Ahmed","Kumar, Abhishek","Macdonald, John"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32473051","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/ccd.29050","keywords":["acute myocardial infarction","antithrombotic treatment","neutrophil extracellular traps","primary percutaneous coronary intervention","viral infection"],"topics":["Case Report"],"weight":1,"_version_":1668255193450414080,"score":348.25085}]}